A Prospective Study of Bone Marrow Hematopoietic and Mesenchymal Stem Cells in Type 1 Gaucher Disease Patients

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Lecourt, Séverine ^a,b,h   Mouly, Enguerran ^c   Freida, Delphine ^a,h   Cras, Audrey ^a,b,h   Ceccaldi, Raphaël ^d   Heraoui, Djazia ^e   Chomienne, Christine ^b   Marolleau, Jean Pierre ^f   Arnulf, Bertrand ^a,c   Porcher, Raphael ^a   Caillaud, Catherine ^g   Vanneaux, Valérie ^a,h   Belmatoug, Nadia ^e   Larghero, Jérôme ^a,b,h  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d Institut Universitaire d'Hématologie   (France)

^e BEAUJON HOSPITAL   (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

^g Institut Cochin   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CELL CYCLE ARREST; CHILD; CONTROLLED STUDY; ENZYME ACTIVITY; GAUCHER DISEASE; GAUCHER DISEASE TYPE 1; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MICROENVIRONMENT; MORPHOLOGY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SCHOOL CHILD;

ADULT; AGED; ANIMALS; BONE MARROW CELLS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR MICROENVIRONMENT; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MICE; MIDDLE AGED; OSTEOBLASTS; OSTEOCLASTS; PROSPECTIVE STUDIES;

EID: 84880781306     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069293     Document Type: Article

References (35)

1. Grabowski GA, (2008) Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372: 1263-1271.
2. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160: 2835-2843.
3. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM, (1997) Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. Qjm 90: 19-25.
4. Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, et al. (1999) Cytokines in Gaucher's disease. Eur Cytokine Netw 10: 205-210.
5. Ciana G, Martini C, Leopaldi A, Tamaro G, Katouzian F, et al. (2003) Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 72: 185-189.
6. de Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, et al. (2008) Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 87: 439-449.
7. Hollak CE, Evers L, Aerts JM, van Oers MH, (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23: 201-212.
8. van Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, et al. (2007) Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 1772: 788-796.
9. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, et al. (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41: 4-14.
10. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, et al. (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113: 112-119.
11. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
12. Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, et al. (2003) Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 10: 228-241.
13. Berger J, Lecourt S, Vanneaux V, Rapatel C, Boisgard S, et al. (2010) Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease. Br J Haematol 150: 93-101.
14. Lecourt S, Vanneaux V, Cras A, Freida D, Heraoui D, et al. (2011) Bone marrow microenvironment in an in vitro model of Gaucher Disease: consequences of Glucocerebrosidase deficiency. Stem Cells Dev.
15. Campeau PM, Rafei M, Boivin MN, Sun Y, Grabowski GA, et al. (2009) Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood 114: 3181-3190.
16. Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, et al. (2010) Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci U S A 107: 19473-19478.
17. Lorincz M, Herzenberg LA, Diwu Z, Barranger JA, Kerr WG, (1997) Detection and isolation of gene-corrected cells in Gaucher disease via a fluorescence-activated cell sorter assay for lysosomal glucocerebrosidase activity. Blood 89: 3412-3420.
18. Rudensky B, Paz E, Altarescu G, Raveh D, Elstein D, et al. (2003) Fluorescent flow cytometric assay: a new diagnostic tool for measuring beta-glucocerebrosidase activity in Gaucher disease. Blood Cells Mol Dis 30: 97-99.
19. Lecourt S, Vanneaux V, Leblanc T, Leroux G, Ternaux B, et al. (2010) Bone marrow microenvironment in Fanconi Anemia: a prospective functional study in a cohort of Fanconi Anemia patients. Stem Cells Dev.
20. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, et al. (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174: 6477-6489.
21. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, et al. (2007) Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21: 158-163.
22. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS, (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107: 1055-1061.
23. Conzelmann E, Sandhoff K, (1983) Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev Neurosci 6: 58-71.
24. Leinekugel P, Michel S, Conzelmann E, Sandhoff K, (1992) Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 88: 513-523.
25. Schueler UH, Kolter T, Kaneski CR, Zirzow GC, Sandhoff K, et al. (2004) Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis 27: 649-658.
26. Hein LK, Duplock S, Hopwood JJ, Fuller M, (2008) Lipid composition of microdomains is altered in a cell model of Gaucher disease. J Lipid Res 49: 1725-1734.
27. Neto H, Collins LL, Gould GW, (2011) Vesicle trafficking and membrane remodelling in cytokinesis. Biochem J 437: 13-24.
28. Mucci JM, Scian R, De Francesco PN, Garcia FS, Ceci R,et al. Induction of osteoclastogenesis in an in vitro model of Gaucher disease is mediated by T cells via TNF-alpha. Gene 509: 51-59.
29. Rudzki Z, Okon K, Machaczka M, Rucinska M, Papla B, et al. (2003) Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease - a histological study. Eur J Haematol 70: 273-281.
30. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494.
31. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr, (2008) Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 42: 669-680.
32. Take I, Kobayashi Y, Yamamoto Y, Tsuboi H, Ochi T, et al. (2005) Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology 146: 5204-5214.
33. Kobayashi Y, Take I, Yamashita T, Mizoguchi T, Ninomiya T, et al. (2005) Prostaglandin E2 receptors EP2 and EP4 are down-regulated during differentiation of mouse osteoclasts from their precursors. J Biol Chem 280: 24035-24042.
34. Enquist IB, Nilsson E, Ooka A, Mansson JE, Olsson K, et al. (2006) Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A 103: 13819-13824.
35. Enquist IB, Nilsson E, Mansson JE, Ehinger M, Richter J, et al. (2009) Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease. Stem Cells 27: 744-752.